Sinovac appoints chief financial officer
pharmafile | June 3, 2013 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing |Â Â China, SinovacÂ
China-based biopharma products provider Sinovac Biotech has appointed vice president Nan Wang to be its chief financial officer.
Previous CFO Danny Chung has resigned for family reasons. Since joining the company in 2001, Wang has served in different senior management roles inclusive of vice general manager of Sinovac Beijing, the firm’s primary operating subsidiary, former general manager of Sinovac Dalian, and as a member of the Board of directors of Sinovac Beijing and Sinovac Dalian.
She oversees Sinovac’s business development, strategic management and investment and was instrumental in leading the Company’s successful public offering in early 2010.
Wang previously served as Interim CFO in 2011 before Chung joined the company. She is actively involved in the company’s investor relations activities.
Weidong Yin, chairman, president and chief executive of Sinovac said: “For more than twelve years, Nan has served as a valuable member of Sinovac’s senior management team and developed a wealth of experience in the vaccine sector, communications with investors, fundraising, and financial management.
“We believe her business experience will bring additional value to the finance team as the company prepares to grow with the introduction of new products. On behalf of the Board, we appreciate Danny’s contributions to the company and wish Danny all the best in his future endeavours.”
Related Content

CARBOGEN AMCIS manufacturing license advances services in China
Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has …

NDA in China receives priority review status for lung cancer treatment
HUTCHMED have announced that the China National Medical Products Administration (NMPA) have granted a priority …

China’s NMPA accepts Everest Medicines’ Nefecon supplementary application
Everest Medicines has announced that China’s National Medical Products Administration (NMPA) has accepted the submission …






